Go Pro
NASDAQ:IVVD

Invivyd Q4 2024 Earnings Report

Invivyd logo
$0.69 +0.00 (+0.34%)
As of 12:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Invivyd EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Invivyd Revenue Results

Actual Revenue
$13.80 million
Expected Revenue
$13.57 million
Beat/Miss
Beat by +$233.00 thousand
YoY Revenue Growth
N/A

Invivyd Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 20, 2025
Conference Call Time
8:00AM ET

Invivyd Earnings Headlines

Elon's next move will be bigger than the IPO – and it could happen any day now
Hedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning streak - says the SpaceX IPO wasn't the main event. It was the trigger. He's identified what he calls the 'Final Phase of Elon's Master Plan,' and one specific ticker he believes could see billions forced into it within days. It's not SpaceX, Tesla, or any company you'd associate with Elon Musk. Larry is revealing the ticker free today.tc pixel
Invivyd (IVVD) Projected to Announce Earnings on Thursday
See More Invivyd Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email.

About Invivyd

Invivyd (NASDAQ:IVVD), a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

View Invivyd Profile